Stryker Co. (NYSE:SYK) Shares Bought by Advisory Alpha LLC

Advisory Alpha LLC grew its holdings in shares of Stryker Co. (NYSE:SYK) by 7.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,901 shares of the medical technology company’s stock after purchasing an additional 206 shares during the period. Advisory Alpha LLC’s holdings in Stryker were worth $1,045,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Dunhill Financial LLC lifted its position in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 37 shares during the last quarter. Centennial Bank AR lifted its holdings in shares of Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Stryker in the 3rd quarter valued at $36,000. HBW Advisory Services LLC acquired a new stake in Stryker during the 3rd quarter worth about $42,000. Finally, Hara Capital LLC purchased a new stake in Stryker during the third quarter valued at about $42,000. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is currently owned by corporate insiders.

Stryker Stock Performance

NYSE:SYK opened at $390.31 on Thursday. The firm’s 50-day moving average is $375.78 and its 200-day moving average is $359.94. The company has a market cap of $148.79 billion, a price-to-earnings ratio of 41.83, a PEG ratio of 2.72 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a 52-week low of $307.23 and a 52-week high of $398.20.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same quarter in the previous year, the firm posted $2.46 EPS. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. Equities research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. Stryker’s dividend payout ratio is 36.01%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on SYK shares. Royal Bank of Canada restated an “outperform” rating and set a $425.00 price target on shares of Stryker in a report on Tuesday, January 7th. JPMorgan Chase & Co. increased their target price on Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. BTIG Research increased their price objective on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, Citigroup raised their price objective on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.